President-elect Donald Trump yesterday named Gen. James Mattis, who also sits on the board of directors at failed biomedical startup Theranos, as his pick for defence secretary. Now the The Washington Post has emails that show General Mattis pushing for Theranos to receive a deal for a military field test from 2012 to 2013, despite the fact that Theranos' devices were far from being FDA approved. Before the company unravelled, it was pushing a vision of breakthrough, low cost medical tools that could analyse blood and do complex analysis quickly and efficiently.